EZH2 and diffuse large B-cell lymphoma: In spite of this, analysis of publicly available data from patients included in two different studies [5]—warranting cautious interpretation, given the potential use of different inclusion and outcome criteria-associates EZH2 mutated DLBCL with worse Overall and Progression Free Survival, albeit not significantly (Figure A1) Furthermore, when considering EZH2 expression, some studies suggest that it may be a promising biomarker in DLBCL [12,13,14,15,16,17,18,19].